| Date | Title | Description |
| 24.02.2026 | bit.bio Accelerates Global Access to Human Cells with New Pricing Model and Distribution Hub | Following a strong $50M funding round, portfolio company bit.bio is leveraging scale and operational efficiencies to significantly lower the price per vial across its ioCells™ portfolio, expanding access to high-quality human cells globally... |
| 14.01.2026 | Biotech Innovator bit.bio Secures $50M to Revolutionize Drug Discovery | bit.bio, a pioneering UK biotech, has secured $50 million in Series C funding, led by M&G Investments. This significant capital infusion will supercharge its human cell programming technology. The company aims to accelerate drug discove... |
| 13.01.2026 | Hadrian Secures $1.6 Billion: Powering U.S. Industrial Future | Hadrian, a leader in automated aerospace and defense manufacturing, just secured $1.6 billion in funding. This capital boosts its valuation to $1.6 billion. T. Rowe Price led the round. The company will expand U.S. factory operations. It ai... |
| 12.01.2026 | Hadrian Raises Funding at $1.6 Billion Valuation | Hadrian, a Los Angeles, California-based developer of automated factories for aerospace and defense, raised expanded capital at a $1.6 billion valuation.
The round wasled by T. Rowe Price Associates, Inc. with participation from Altimeter C... |
| 12.01.2026 | bit.bio Raises $50M in Funding | bit.bio, a Cambridge, UK-based biotech company leveraging human cell programming technology, raised $50M in funding.
The round was led by M&G Investments.
The company intends to use the funds to accelerate the development of, and access... |
| 11.01.2026 | bit.bio Raises $50 Million Series C Led by M&G To Scale Human Cell Programming Platform | M&G Investments has led a $50 million Series C funding round for bit.bio, a Cambridge-based biotechnology company developing human cell programming technology to improve the speed and predictability of drug discovery and safety testing.... |
| 21.08.2025 | Meatable acquires Uncommon Bio’s cultivated meat platform as latter pivots to therapeutics | Dutch startup Meatable has acquired the cultivated meat platform of UK-based Uncommon Bio, including key technology, several IP assets, select cell lines, and key staff, for an undisclosed sum.
The move comes as Uncommon Bio pivots away fro... |
| 01.05.2025 | Meatable aims to start construction of pilot-scale cultivated meat facility in Singapore later this year | Dutch startup Meatable has teamed up with a newly formed company called TruMeat to build a cultivated meat facility in Singapore.
TruMeat is run by executives with significant experience in large-scale biomanufacturing and cell culture medi... |
| 19.12.2024 | bit.bio raises $30 Million led by M&G Investments | bit.bio raises $30 Million led by M&G Investments to focus on tools for the research, drug discovery and cell therapy markets.
Jonathan Milner appointed Interim CEO; Mark Kotter assumes Vice Chairman role as Company expands Board with d... |
| 06.08.2024 | bit.bio expand Executive Team with appointment of Przemek Obloj as Chief Financial Officer | Cambridge, UK – bit.bio, the company coding human cells for novel cures and a pioneer in the field of synthetic biology, announces the appointment of Przemek Obloj as Chief Financial Officer. Mr. Obloj will oversee the company’s financial s... |
| 29.07.2024 | Cultivated meat is down but not out, says meat industry veteran and new CEO at Meatable | Cultivated meat may be down, but it’s not out, insists the new US-based CEO of Dutch startup Meatable. The reason is simple, claims Jeff “Trip” Tripician, a meat industry veteran who took the helm of the company last month. “Our supply chai... |
| 28.03.2024 | Meatable CTO on the cultivated meat industry cycle: ‘Hype, stagnation, consolidation, redirection’ | Dutch startup Meatable has slashed production times for cultivated pork in recent months by dramatically speeding up the process by which its stem cells differentiate into fat and muscle, further improving its unit economics at a time when ... |
| 07.08.2023 | Dutch cultivated meat startup Meatable raises $35m Series B, gears up for market entry in 2024 | Dutch cultivated meat startup Meatable has raised $35 million in a series B round led by Agronomics, taking its total funding to $95 million as it gears up to launch pork sausages and dumplings in Singapore next year.
The round includes $17... |
| 30.05.2023 | 🎥 Meatable CEO: ‘We believe we have the fastest process in the field to make cultivated meat’ | Dutch startup Meatable has slashed production times for cultivated pork from three weeks to eight days in the past year by dramatically speeding up the process by which its stem cells differentiate into fat and muscle, transforming its unit... |
| 23.05.2023 | This Record Breaking Dutch Startup Just Made Cultivated Meat In 8 Days | Meatable cofounders with new pork product, dumplingsMeatable |
| 16.01.2023 | Какие технологии нужны ЕС? ТОП-10 технологических сфер для стартапов в Европе | Чтобы быть конкурентоспособной, Европе нужно укреплять свои позиции на рынке технологий. Мы составили топ-10 технологических сфер наиболее актуальные для Европы. Сегодня в этих отраслях наблюдается рост рабочих мест, а стартапы, которые акт... |
| 08.11.2021 | Bit.bio secures $103M | Bit.bio has raised a $103 million Series B from investors including Arch Ventures, Foresite Capital and Charles River Laboratories. Based in San Francisco and the UK, the company is a developer of cell coding technology intended to discover... |
| 08.11.2021 | U.K.-based bit.bio secures €89.1M to expedite gene engineering technology to fight diseases | Cambridge, UK-based bit.bio, a human cell coding company, raised $103M (approx €89.1M) in a Series B round of funding. Arch Ventures, Charles River Laboratories, Foresite Capital, Resilience, Metaplanet, Puhua Capital, and Tencent participa... |
| 05.11.2021 | bit.bio raises $103 million in first close of Series B financing | Today bit.bio announces the first close of its Series B financing of $103 million. The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.
New and existing institutional a... |
| 05.11.2021 | bit.bio Raises in Excess of $100 Million in First Close of Series B Financing | Human cell coding company bit.bio today announces the first close of their Series B financing of $103 million.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211105005429/en/
bit... |
| 05.11.2021 | bit.bio raises $103 million in first close of Series B financing | bit.bio raises $103 million in first close of Series B financing
05-11-2021
Today bit.bio announces the first close of its Series B financing of $103 million. The funding will accelerate clinical development of cell therapies using breakthr... |
| 16.06.2020 | Bit Bio secures $41.5 million of funding from top life science investors | Bit Bio, a Cambridge-based synthetic biology company combining data science and biology to code cells for the wellbeing of humanity, has announced the close of a $41.5 million Series A investment, bringing the company’s total funding to $50... |
| 16.06.2020 | Bit Bio secures $41.5 million of funding from top life science investors | Bit Bio secures $41.5 million of funding from top life science investors
16-06-2020
Bit Bio, a Cambridge-based synthetic biology company combining data science and biology to code cells for the wellbeing of humanity, has announced the close... |
| 15.06.2020 | Компания по производству человеческих клеток Bit Bio привлекла $41,5 млн: она хочет сделать генную терапию доступнее Статьи редакции... | Bit Bio работает над технологией, которая удешевит выращивание человеческих клеток для генной терапии и ускорит создание новых лекарств.
3 3 комментария
2219 просмотров
Основанный в Кембриджском университете стартап Bit Bio с 2016 года разр... |
| 14.06.2020 | Bit Bio’s ‘enter button for the keyboard to the software of life’ nabs the company $41.5 million | Jonathan Shieber of Tech Crunch writes about Bit Bio's technoloigy and its latest funding round.
Read the full article here |
| 14.06.2020 | Bit Bio’s ‘enter button for the keyboard to the software of life’ nabs the company $41.5 million | Bit Bio, the new startup that pitches itself as the “enter button for the keyboard to the software of life,” only needed three weeks to raise its latest $41.5 million round of funding.
Originally known as Elpis Biotechnology and named for t... |
| - | Bit.bio | “With our opti-ox™ technology, we precisely, consistently, & efficiently reprogram stem cells into any cell type at scale for your research needs. Learn more!” |
